Pfkelch13 mutations occur in 6% of Plasmodium falciparum isolates across various African regionsNew Data Shows Regional Differences in Malaria Drug Resistance

medRxiv Published June 11, 2026 Study authors: Munyangi wa Nkola, J.; Akilimali Zalagile, P.; Lukuke Mbutshu, H.; Kabala Munyemo, S.; Ramazani Bin … DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that pfkelch13 mutation prevalence varies significantly by region, reaching 25.5% in Northern Uganda.

This meta-analysis synthesizes data from observational cohort studies to determine the prevalence of pfkelch13 mutations in Plasmodium falciparum isolates across Africa. The study analyzed 888 isolates to assess both the overall prevalence and the geographic distribution of these mutations, which are linked to artemisinin resistance.

The primary finding is a pooled prevalence of validated pfkelch13 mutations of 6% (95% CI: 2.1%-11.8%). Regional data showed significant variation: Rwanda reported a prevalence of 12.8%, Northern Uganda reached 25.5%, while West and Central African cohorts reported 0%. These results highlight the heterogeneous distribution of genetic markers associated with artemisinin resistance.

The authors note high statistical heterogeneity as a limitation of the study. While the data highlights geographic differences in mutation prevalence, specific clinical indicators for artemisinin partial resistance were noted as objectives but not detailed with specific data points. The findings suggest that standardized surveillance is essential to adapt malaria control policies across the continent.

How this fits prior evidence

This meta-analysis addresses a gap in regional monitoring of genetic markers for drug resistance. It complements existing knowledge on malaria risk reduction from RTS,S/AS01 and R21/Matrix-M vaccines by providing data on the underlying genetic landscape of Plasmodium falciparum. While previous reviews noted a lack of reported data on interventions and outcomes in some malaria literature, this meta-analysis provides specific prevalence figures for pfkelch13 mutations across different African regions.

Researchers analyzed 888 samples of the Plasmodium falciparum parasite from patients across Africa. They looked specifically for pfkelch13 mutations, which are linked to partial resistance against artemisinin, a standard medication used to treat malaria.

The study found that these mutations vary greatly depending on where they were found. While no mutations were found in West and Central African samples, the prevalence was much higher in other regions. Specifically, 12.8% of samples from Rwanda and 25.5% of samples from Northern Uganda showed these mutations.

Because these mutations are linked to drug resistance, this data helps experts understand where malaria treatment might be less effective. However, because this was an observational study with high statistical variation, the results show a link between location and mutation rather than a direct cause of clinical failure. This information is intended to help health officials improve local malaria control policies.

What this means for you:

Mutation levels linked to malaria drug resistance vary significantly by region across Africa.

Common questions

What did the study find about malaria drug resistance?

The study found a 6% overall prevalence of pfkelch13 mutations across the samples. These mutations are linked to partial resistance against artemisinin, which is a common medication used to treat malaria infections in patients.

Does the risk of drug resistance vary by location?

Yes, the study found significant regional differences. While no mutations were found in West and Central African samples, 12.8% were found in Rwanda and 25.5% were found in Northern Uganda.

How can this information help patients with malaria?

This data helps health officials create better surveillance and control policies. By tracking where mutations occur, they can better adapt treatment plans to ensure medications remain effective for people in different regions.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Background: Artemisinin-based combination therapies remain the mainstay of malaria control strategies; nevertheless, the advent of genetic markers linked to partial artemisinin resistance in Plasmodium falciparum has elicited substantial concern across African settings. To assess the prevalence, geographic distribution, and clinical associations of these molecular markers, we undertook a systematic review and meta-analysis of observational cohort studies.Methods: We conducted a search of cohort studies published between January 2015 and June 2025, following PRISMA 2020 guidelines. We queried databases including PubMed/MEDLINE, Scopus, Web of Science, and CINAHL. Eligibility required prospective enrollment of patients, longitudinal monitoring (therapeutic efficacy studies), and pfkelch13 propeller domain genotyping.Results: A meta-analytical synthesis of 888 isolates from six core prospective cohorts revealed a pooled prevalence of 6% (95% CI: 2.1%-11.8%) for validated pfkelch13 mutations. A profound geographic dichotomy was identified: while West and Central African cohorts maintained a 0% prevalence, East African hotspots showed significant expansion, with prevalence reaching 12.8% in Rwanda and up to 25.5% in Northern Uganda; high statistical heterogeneity (, ) reflects this biological divergence. Conclusions: These findings highlight the established and expanding presence of artemisinin partial resistance in East Africa. Standardized surveillance is essential to adapt malaria control policies across the continent. Keywords: Africa; artemisinin resistance; clinical indicators; pfkelch13 gene; molecular markers; partial resistance; Plasmodium falciparum.

Pfkelch13 mutations occur in 6% of Plasmodium falciparum isolates across various African regionsNew Data Shows Regional Differences in Malaria Drug Resistance

How this fits prior evidence

Common questions

Study Details

Genotype-Guided SSRI Prescribing Shows No Short-Term Benefit but Higher Remission at 6 Months

Genetic Testing Helps Some Depression Patients Feel Better Long Term

Clinical research that matters. Delivered to your inbox.

Pfkelch13 mutations occur in 6% of Plasmodium falciparum isolates across various African regionsNew Data Shows Regional Differences in Malaria Drug Resistance

How this fits prior evidence

Common questions

More on Malaria

Study Details

Genotype-Guided SSRI Prescribing Shows No Short-Term Benefit but Higher Remission at 6 Months

Genetic Testing Helps Some Depression Patients Feel Better Long Term

Clinical research that matters. Delivered to your inbox.

Related in Genetics & Precision Medicine

From Other Specialties